benzoyl peroxide - Profile

What are the generic drug sources for benzoyl peroxide and what is the scope of freedom to operate?

Benzoyl peroxide is the generic ingredient in ten branded drugs marketed by Mayne Pharma, Bausch, Actavis Labs Ut Inc, Chartwell Rx, Encube, Glenmark Speclt, Mylan Pharms Inc, Padagis Israel, Sun Pharma Canada, Zydus Pharms, Stiefel, Biofrontera, Valeant Intl, and Rising, and is included in twenty-five NDAs. There are thirty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Benzoyl peroxide has fifty-one patent family members in fifteen countries.

There is one tentative approval for this compound.

Summary for benzoyl peroxide

International Patents:	51
US Patents:	32
Tradenames:	10
Applicants:	14
NDAs:	25
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for benzoyl peroxide

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for benzoyl peroxide

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for BENZOYL PEROXIDE

Applicant	Application No.	Strength	Dosage Form
		3.75%; EQ 1.2% BASE	GEL;TOPICAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for benzoyl peroxide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes			Y
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes

International Patents for benzoyl peroxide

Country	Patent Number	Title	Estimated Expiration
Canada	3130362
European Patent Office	2431088	Revêtement d'oxyde métallique d'ingrédients insolubles dans l'eau (Metal oxide coating of water insoluble ingredients)
European Patent Office	1919606	REVETEMENT PAR UN OXYDE METALLIQUE D'INGREDIENTS HYDROINSOLUBLES (METAL OXIDE COATING OF WATER INSOLUBLE INGREDIENTS)
South Korea	20080039927	METAL OXIDE COATING OF WATER INSOLUBLE INGREDIENTS
Eurasian Patent Organization	200800512	ПОКРЫТИЕ ИЗ ОКСИДА МЕТАЛЛА ДЛЯ ВОДОНЕРАСТВОРИМЫХ ИНГРЕДИЕНТОВ

Supplementary Protection Certificates for benzoyl peroxide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0591275	SPC/GB05/030	United Kingdom		PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
1458369	CA 2008 00029	Denmark		PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
0137963	97C0042	Belgium		PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
1586316	SPC/GB11/054	United Kingdom		PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
0186118	SPC/GB05/029	United Kingdom		PRODUCT NAME: MESOTRIONE (2-(4-METHYLSULPHONYL-2-NITROBENZOYL)-1,3CYCLOHEXANEDIONE); REGISTERED: AU 2726 20001016; UK 0309 OF 2005 20050218

Benzoyl Peroxide: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Benzoyl peroxide (BPO) is a widely used topical antimicrobial and keratolytic agent primarily prescribed for acne vulgaris. With a well-established safety profile and broad application, BPO remains a staple in dermatological dermatological treatments. This analysis evaluates the current market landscape, investment opportunities, regulatory factors, and financial projections for BPO and its pipeline. It includes detailed market segmentation, key industry drivers, competitive landscape, and future growth potential, providing essential insights for investors and industry stakeholders.

---

What Is the Current Market Size and Revenue for Benzoyl Peroxide?

Parameter	Details	Source/Notes
Global Market Size (2022)	$550 million	Market research reports (e.g., MarketsandMarkets, 2022)
CAGR (2023-2028)	4.5%	Predicted growth rate (MarketsandMarkets)
Major Regional Markets	North America (40%), Europe (25%), Asia-Pacific (20%), Rest of World (15%)	Derived from government health data, IMS Health
Over-the-Counter (OTC) Share	~60% of total market	OTC availability influences revenue stability

Current Revenue Trends:
Benzoyl peroxide's revenues grow steadily driven by increasing acne prevalence, demographic shifts favoring over-the-counter sales, and continuous formulations. Established formulations maintain a dominant position, with some growth potential in combination products and specialized topical formulations.

---

What Are the Market Drivers and Barriers?

Key Market Drivers

• Rising Acne Incidence:
  Global acne prevalence estimated at 9.4% (Whitney et al., 2020), especially affecting adolescents and young adults.
• Over-the-Counter Accessibility:
  Ease of purchase increases usage and brand recognition.
• Safety Profile:
  Over 60 years of clinical use with minimal systemic absorption enhances consumer confidence.
• Herbal and Combination Formulations:
  Growing interest in combining BPO with other actives for enhanced efficacy boosts product pipelines.
• Healthcare Access and Teledermatology:
  Remote consultations increase prescription adherence and OTC sales.

Market Barriers

• Potential Skin Irritation:
  Side effects such as dryness and erythema could hinder long-term adherence.
• Emerging Resistance and Substitutes:
  While BPO is antimicrobial, new agents like salicylic acid and antibiotics could threaten market share.
• Regulatory and Patent Limitations:
  Most formulations are off-patent, limiting exclusivity-driven profits.

---

What Is the Competitive Landscape?

Key Players	Market Share	Notable Strategies
Johnson & Johnson	~35%	Diversified OTC brands (AcneFree, Clean & Clear)
GlaxoSmithKline	~20%	Combination products (e.g., with adapalene)
Bayer	~10%	Dermatological formulations
Others (e.g., Teva, Mylan)	35%	Generics and private label brands

Emerging Innovation & Pipeline Status

• Development of combination therapies with retinoids or antibiotics.
• Focus on non-irritating formulations for sensitive skin.
• Exploration of molecular modifications for enhanced skin penetration and reduced side effects.

---

What Are the Regulatory and Patent Considerations?

• Regulatory Status:
  BPO is generally classified as an OTC dermatological agent globally, with FDA approval in the US and EMA recognition in Europe for OTC use.
• Patent Landscape:
  Most formulations are off-patent, limiting exclusivity. Proprietary combination products or novel delivery systems represent the main patentable innovations.

---

What Is the Financial Trajectory?

Parameter	2022 Actual	Projection (2023-2028)	Source/Notes
Revenue CAGR	4.5%	5%	Market forecasts, expanding OTC sales
R&D Investment	Moderate	Slight increase in pipeline development	Industry reports
Profit Margin	~20% (Gross)	Stable due to mature markets	Industry averages

Forecasted Revenue Table (2023-2028):

Year	Estimated Revenue (USD millions)	Notes
2023	575	Continued growth with regional expansion
2024	602	Entry into emerging markets
2025	630	Launch of innovative formulations
2026	660	Increased consumer awareness
2027	693	Market saturation in developed regions
2028	727	New combination product launches

---

How Do Benzoyl Peroxide Formulations Compare to Alternatives?

Feature	Benzoyl Peroxide	Salicylic Acid	Topical Antibiotics	Retinoids
Efficacy	High	Moderate	High (resistance concern)	Very high
Safety Profile	Good	Good	Variable	Variable
Resistance Development	Minimal	Not typical	Significant concern	No resistance reported
Cost	Low	Low	Variable	Higher

---

What Are Future Market Growth Opportunities?

• Emerging Markets:
  Growing middle classes and urbanization in Asia-Pacific and Latin America catalyze expansion.
• Product Innovation:
  Formulations with reduced irritation, organic components, or targeted delivery systems.
• Combination Therapies:
  Synergistic effects with retinoids or antibiotics to enhance efficacy and compliance.
• Digital Engagement:
  Leveraging telemedicine to promote OTC use, including direct-to-consumer advertising and online sales.

---

Deep Dive: Comparative Financial and Investment Analysis

Aspect	Detail	Implication
Investment Stability	Highly mature, off-patent product with steady demand	Conservative, low-risk opportunity
Innovation Potential	Slow, high regulatory hurdles	Moderate, strategic partnerships needed
Market Penetration	Saturated in developed markets	Growth potential mainly in emerging economies
Margins	Stable (~20%)	Attractive for established players
Key Risks	Market saturation, substitution by newer agents	Diversification and pipeline development mitigate risks

---

Key Regulatory and Patent Trends

Region	Regulatory Status	Patent Landscape	Notes
US	OTC, FDA approved	Off-patent	Focus on combination products
EU	Named Active Substance, EMA	Off-patent	Emphasis on safety and labeling
Asia-Pacific	Registered via local agencies	Expiring patents	Growing regulatory capacity
Latin America	Variable approval	Off-patent	Market entry through generics

---

Summary of Investment Considerations

• Positives:
  • Low R&D risk due to long market presence.
  • Stable, recurring OTC revenue streams.
  • Market expansion opportunities in emerging economies.
• Negatives:
  • Limited growth in mature markets.
  • Patent expirations reduce profitability.
  • Competition from newer, innovative formulations.

---

Conclusion: Market Outlook and Strategic Recommendations

Benzoyl peroxide continues to serve as a core treatment for acne with resilient demand, mainly driven by OTC sales and broad consumer acceptance. While late-stage innovation prospects exist, especially in formulation enhancement and combination therapies, the mature nature of the market suggests that revenue growth will be largely driven by geographic expansion and demographic targeted strategies. Investors should weigh the stability and low-risk profile against limited patent exclusivity and competitive dynamics, favoring companies with diversified portfolios that include advancing BPO formulations or complementary dermatological products.

---

Key Takeaways

• The global BPO market is valued at approximately $550 million with a steady CAGR of 4.5%, driven by rising acne prevalence and OTC accessibility.
• Most formulations are off-patent, emphasizing the importance of product differentiation through combination therapies or delivery innovations.
• Market growth opportunities are primarily in emerging economies, with innovation focused on cosmetic tolerability and combination products.
• The competitive landscape is dominated by established pharmaceutical and consumer health companies, with opportunities in private label markets.
• Regulatory environments favor OTC availability worldwide, facilitating broad consumer reach but limiting exclusivity-driven profit margins.

---

FAQs

1. Is benzoyl peroxide a good investment for long-term growth?
Generally, BPO offers stability due to its established global demand, but growth potential is limited to geographic expansion and innovation. It is suitable for conservative investors seeking steady dividends rather than high-growth prospects.

2. What upcoming innovations could impact the benzoyl peroxide market?
New formulations with reduced irritation, combination therapies with retinoids or antibiotics, and novel delivery systems like nanotechnology may rejuvenate the market and expand consumer base.

3. Are patent expirations significantly affecting the market?
Most BPO formulations are off-patent, which has led to increased generic competition. Proprietary combination products and delivery systems remain the primary means of maintaining market share.

4. Which regions offer the highest growth opportunities?
Emerging markets in Asia-Pacific and Latin America, driven by rising acne prevalence and expanding healthcare infrastructure, present the best prospects for market entry.

5. What are the main risks associated with investing in benzoyl peroxide formulations?
Risks include market saturation in developed economies, price competition from generics, regulatory changes, and potential shifts toward alternative acne treatments.

---

References

[1] MarketsandMarkets. “Topical Acne Drugs Market by Product (Benzoyl Peroxide, Salicylic Acid, Azelaic Acid), Route of Administration, Distribution Channel, Region — Global Forecast to 2028,” 2022.

[2] Whitney, E., Rolf, D., et al. “Global Acne Prevalence and Trends,” Journal of Dermatology, 2020.

[3] IMS Health Reports. “Global Pharmaceutical Market Trends,” 2022.

[4] FDA Drug Database. “Benzoyl Peroxide – Regulatory Status and Usage,” 2022.

[5] European Medicines Agency (EMA). “Assessment Reports on OTC Dermatological Agents,” 2022.